FRMM
Forum Markets Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Forum Markets Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
No other changes.
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Annual filing, covered
10-K parsed · Apr 1 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Apr 1 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: American Express Co, Coinbase Global, Inc., Synchrony Financial and 3 more; no measured co-movers for Forum Markets Inc.
Same SIC code · 6
Same SEC industry code: American Express Co, Coinbase Global, Inc., Synchrony Financial and 3 more; no measured co-movers for Forum Markets Inc.
Forum Markets Inc
3.35
—
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Susquehanna International | $21.4M | 43.52% | +3.13% |
| Stokes Family Office | $5.2M | 10.60% | +24.81% |
| Vise Technologies | $4.7M | 9.48% | new |
| Citadel | $3.1M | 6.38% | +9.14% |
| Saba | $2.0M | 4.11% | −22.71% |
| Manager | Value | % base | |
|---|---|---|---|
| Susquehanna International | $21.4M | 43.52% | +3.13% |
| Stokes Family Office | $5.2M | 10.60% | +24.81% |
| Vise Technologies | $4.7M | 9.48% | new |
| Citadel | $3.1M | 6.38% | +9.14% |
| Saba | $2.0M | 4.11% | −22.71% |
Bull1
Bear2
Expected move
No implied move.